Navigation Links
First targeted and programmable nanomedicine to show clinical antitumor effects published
Date:4/4/2012

Cambridge, MA, April 4, 2012 BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, that are capable of up to a ten-fold increase in drug concentration at tumor sites, has published preclinical and clinical data in Science Translational Medicine showing promising effects in solid tumors and successful clinical translation of BIND-014, the first targeted and programmed nanomedicine to enter human clinical studies.

In the paper titled "Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile," BIND scientists describe BIND-014's ability to concentrate in tumors and provide preclinical and clinical data demonstrating efficacy, safety and pharmacological properties that are superior to and highly differentiated from the parent chemotherapeutic drug, docetaxel. BIND-014 is the first clinical-stage targeted therapeutic nanoparticle with programmable pharmacological properties, including particle circulation time, pharmacokinetic profile, biodistribution and release profile. BIND-014 has been shown to effectively target a receptor expressed in tumors to achieve high drug concentrations at the site of disease.

"These seminal data on BIND's first clinical stage Accurin, BIND-014, demonstrates for the first time that it is possible to generate medicines with both targeted and programmable properties that can concentrate the therapeutic effect directly at the site of disease, potentially revolutionizing how complex diseases such as cancer are treated," commented Omid Farokhzad, M.D, BIND Founder and Associate Professor, Harvard Medical School. "BIND's data are a giant leap forward in achieving the true promise of nanomedicine by enabling the design of therapeutics with highly-differentiated efficacy and safety that go above and beyond the capabilities of traditional drug
'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412
The Yates Network
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. MiMedx Exceeds Revenue Goal for First Quarter of 2012
2. FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
3. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
4. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
5. Researchers capture first-ever images of atoms moving in a molecule
6. Be One of the First to Experience Medtrack One View at the AUTM 2012 Annual Meeting
7. First Statewide Biotech Meeting Focuses on Patient Access, Innovation
8. Inaugural Meeting of the FirstMark Scientific Board of Advisors
9. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
10. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
11. Penn researchers build first physical metatronic circuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Bryan-College Station, Texas (PRWEB) September 18, 2014 ... University System Chancellor John Sharp, Texas A&M Health ... from the U.S. Department of Health and Human ... GSK today dedicated a national pandemic influenza vaccine ... will serve as an anchor for the Texas ...
(Date:9/18/2014)... Research and Markets has announced the addition ... report to their offering. The ... and in-depth study on the current state of the ... a basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including development ...
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  MEI Pharma, Inc. ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at BioCentury,s NewsMakers in the ... 8:30 a.m. Eastern time from the Millennium Broadway Hotel & ... live webcast of the presentation can be accessed at ...
(Date:9/18/2014)... , Sept. 18, 2014   Sigma-Aldrich ... it has entered into a new gene editing ... School,s Vector Core. Under the partnership, Sigma-Aldrich will ... experimental design consultation, and dedicated gene editing bioinformaticians. ... gene editing-based research at the U-M Medical School. ...
Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... ST. PAUL, Minn., Jan. 3 /Xinhua-PRNewswire/ --,WuXi ... provider of pharmaceutical R&D,outsourcing services, has signed ... Services, Inc. (AppTec). The acquisition of AppTec ... and expertise,gain a significant U.S. operational footprint, ...
... Pharmos Corporation,(Nasdaq: PARS ) announced today ... private placement of its 10% Convertible Debentures due ... $4,000,000 principal amount of the,Debentures, at par, and ... The purchasers consisted of certain existing investors in ...
... Jan. 3 TAP Pharmaceutical Products,Inc. today announced the ... Food and Drug Administration (FDA) for the use of ... and maintenance of,patients with erosive esophagitis and non-erosive reflux ... novel delivery system., "This compound and its novel ...
Cached Biology Technology:WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 2WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 3WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 4WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 5Pharmos Corporation Completes Initial Closing of Private Placement 2
(Date:9/17/2014)... the Copenhagen Centre for Social Evolution and Yale University ... birth weight and -length can partially predict the likelihood ... autism and schizophrenia later in life. The study analyzed ... hospital diagnoses for up to 30 years, and adjusted ... is published today in the Proceedings of the ...
(Date:9/17/2014)... first partial genome sequence of an ancient pig. Extracted ... of the Montsoriu Castle in Girona, the data obtained ... today,s Iberian pig. Researchers also discard the hypothesis that ... The study, published in Heredity , sheds new ... on that of the Iberian breed, considered to be ...
(Date:9/17/2014)... EAST LANSING, Mich. Mutations in the human retinoblastoma ... Now, Michigan State University scientists have turned to fruit ... cancer gene. , In a paper featured on ... Journal of Biological Chemistry , Michigan State University researchers ... mutations similar to those present in the human cancer ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Iberian pig genome remains unchanged after 5 centuries 2Abnormal properties of cancer protein revealed in fly eyes 2
... has found that a little-understood disease study authors are ... bee larvae, is the largest risk factor for predicting ... seen symptoms similar to IBDS associated with viruses spread ... Tarpy, an associate professor of entomology at North Carolina ...
... South Atlantic Ocean can be used to accurately forecast, ... miles away in northwestern India, a University of Michigan ... July sea surface temperatures in the tropical South Atlantic ... epidemics in the arid and semi-arid regions of northwest ...
... by researchers at the University of California, San ... produced the most comprehensive virtual reconstruction of human ... known as Recon 2, to identify causes of ... and even psychiatric and neurodegenerative disorders. Each person,s ...
Cached Biology News:Researchers id queens, mysterious disease syndrome as key factors in bee colony deaths 2Early warning system provides 4-month forecast of malaria epidemics in northwest India 2International consortium builds 'Google Map' of human metabolism 2International consortium builds 'Google Map' of human metabolism 3International consortium builds 'Google Map' of human metabolism 4